FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

Jan 16, 2024

GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS

CAUTION: Investigational device. Limited by United States law to investigational use.

Apr 12, 2022

COVID-19: Our Current Path Forward

GORE REDUCE CLINICAL STUDY FIVE-YEAR RESULTS DEMONSTRATE THAT PFO CLOSURE WITH THE GORE® CARDIOFORM SEPTAL OCCLUDER PROVIDES SAFE LONG-TERM REDUCTION OF RECURRENT STROKE

FIVE-YEAR RESULTS OF THE GORE® EXCLUDER® ILIAC BRANCH ENDOPROSTHESIS PIVOTAL U.S. MULTICENTER STUDY CONFIRM SAFETY, EFFICACY AND DURABILITY

Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure

Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone

Gore Joins Vascular and Endovascular Leaders in Recognizing the 2016 Pioneers in Performance for North America

Leading Practitioners and Researchers from North America Commended for Commitment to Advancing Vascular and Endovascular Therapy

FDA Approves GORE® VIABAHN® Endoprosthesis for Revision of the Arteriovenous Access

Flexibility and Durability to Aid Hemodialysis Patients

Gore REDUCE Clinical Study Completes Enrollment

Study of Closure of Patent Foramen Ovale (PFO) in Stroke Patients Reaches Major Milestone

Gore Recognized as one of the Worlds Best Multinational Workplaces by Great Place to Work®

Company earns No. 3 spot